MicroRNA‑100 inhibits breast cancer cell proliferation, invasion and migration by targeting FOXA1

Xie,Haihui; Xiao,Ruobing; He,Yaolin; He,Lingzhi; Xie,Changjun; Chen,Juan; Hong,Yan

doi:10.3892/ol.2021.13077

MicroRNA‑100 inhibits breast cancer cell proliferation, invasion and migration by targeting FOXA1

Authors:
- Haihui Xie
- Ruobing Xiao
- Yaolin He
- Lingzhi He
- Changjun Xie
- Juan Chen
- Yan Hong
View Affiliations

Affiliations: Department of Radiation Oncology, The Second Affiliated Hospital University of South China, Hengyang, Hunan 421001, P.R. China, Department of Preventive Medicine, Hunan Polytechnic of Environment and Biology, Hengyang, Hunan 421001, P.R. China
Published online on: October 1, 2021 https://doi.org/10.3892/ol.2021.13077
Article Number: 816
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are highly conserved single‑stranded small non‑coding RNAs, which are involved in the physiological and pathological processes of breast cancer, and affect the prognosis of patients with breast cancer. The present study used the Gene Expression Omnibus (GEO)2R tool to detect miR‑100 expression in breast cancer tissues obtained from GEO breast cancer‑related datasets. Bioinformatics analysis revealed that miR‑100 expression was downregulated in different stages, grades and lymph node metastasis stages of breast cancer, and patients with high miR‑100 expression had a more favorable prognosis. Based on these analyses, Cell Counting Kit‑8, wound healing and Transwell assays were performed, and the results demonstrated that overexpression of miR‑100 inhibited the proliferation, migration and invasion of breast cancer cells. To verify the tumor‑suppressive effect of miR‑100 in breast cancer, the LinkedOmics and PITA databases were used to assess the association between miR‑100 and forkhead box A1 (FOXA1). The results demonstrated that miR‑100 had binding sites within the FOXA1 gene, and FOXA1 expression was negatively associated with miR‑100 expression in breast cancer tissues. Similarly, a negative association was observed between miR‑100 and FOXA1 expression, using the StarBase V3.0 database. The association between miR‑100 and FOXA1 was further verified via reverse transcription‑quantitative PCR and western blot analyses, and the dual‑luciferase reporter assay. The results demonstrated that miR‑100 targeted the 3'‑untranslated region of FOXA1 in breast cancer cells. Furthermore, rescue experiments were performed to confirm whether miR‑100 exerts its antitumor effects by regulating FOXA1. The results demonstrated that overexpression of FOXA1 promoted the proliferation, migration and invasion of breast cancer cells; thus, the antitumor effects of miR‑100 in breast cancer were reversed following overexpression of FOXA1. Taken together, the results of the present study suggest that miR‑100 inhibits the proliferation, migration and invasion of breast cancer cells by targeting FOXA1 expression. These results may provide a novel insight and an experimental basis for identifying effective therapeutic targets of high specificity for breast cancer.

View Figures

View References

1	Yin X, Wang P, Yang T, Li G, Teng X, Huang W and Yu H: Identification of key modules and genes associated with breast cancer prognosis using WGCNA and ceRNA network analysis. Aging (Albany NY). 13:2519–2538. 2020. View Article : Google Scholar : PubMed/NCBI
2	Fahad Ullah M: Breast cancer: Current perspectives on the disease status. Adv Exp Med Biol. 1152:51–64. 2019. View Article : Google Scholar : PubMed/NCBI
3	Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C and Foti M: Deciphering miRNAs' action through miRNA editing. Int J Mol Sci. 20:62492019. View Article : Google Scholar : PubMed/NCBI
4	Chen M, Chen C, Luo H, Ren J, Dai Q, Hu W, Zhou K, Tang X and Li X: MicroRNA-296-5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor-β-induced epithelial-mesenchymal transition. Cell Mol Biol Lett. 25:492020. View Article : Google Scholar : PubMed/NCBI
5	Zhu Z, Luo L, Xiang Q, Wang J, Liu Y, Deng Y and Zhao Z: MiRNA-671-5p promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis. Cell Death Dis. 11:9492020. View Article : Google Scholar : PubMed/NCBI
6	Vinchure OS and Kulshreshtha R: miR-490: A potential biomarker and therapeutic target in cancer and other diseases. J Cell Physiol. 236:3178–3193. 2021. View Article : Google Scholar : PubMed/NCBI
7	Wu H, Mu X, Liu L, Wu H, Hu X, Chen L, Liu J, Mu Y, Yuan F, Liu W and Zhao Y: Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 11:8012020. View Article : Google Scholar : PubMed/NCBI
8	Pan C, Stevic I, Müller V, Ni Q, Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol. 12:1935–1948. 2018. View Article : Google Scholar : PubMed/NCBI
9	Jamali L, Tofigh R, Tutunchi S, Panahi G, Borhani F, Akhavan S, Nourmohammadi P, Ghaderian SMH, Rasouli M and Mirzaei H: Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J Cell Physiol. 233:8538–8550. 2018. View Article : Google Scholar : PubMed/NCBI
10	Feng H, Gu ZY, Li Q, Liu QH, Yang XY and Zhang JJ: Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. J Ovarian Res. 12:352019. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Wössner N, Alhalabi Z, González J, Swyter S, Gan J, Schmidtkunz K, Zhang L, Vaquero A, Ovaa H, Einsle O, et al: Sirtuin 1 inhibiting thiocyanates (S1th)-a new class of isotype selective inhibitors of NAD⁺ dependent lysine deacetylases. Front Oncol. 10:6572020. View Article : Google Scholar : PubMed/NCBI
13	Rouleau S, Glouzon JS, Brumwell A, Bisaillon M and Perreault JP: 3′UTR G-quadruplexes regulate miRNA binding. RNA. 23:1172–1179. 2017. View Article : Google Scholar : PubMed/NCBI
14	Chen L, Heikkinen L, Wang C, Yang Y, Sun H and Wong G: Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 20:1836–1852. 2019. View Article : Google Scholar : PubMed/NCBI
15	Cao T and Zhen XC: Dysregulation of miRNA and its potential therapeutic application in schizophrenia. CNS Neurosci Ther. 24:586–597. 2018. View Article : Google Scholar : PubMed/NCBI
16	Linna-Kuosmanen S, Bosch V, Moreau P, Moreau PR, Bouvy-Liivrand M, Niskanen H, Kansanen E, Kivelä A, Hartikainen J, Hippeläinen M, et al: NRF2 is a key regulator of endothelial microRNA expression under proatherogenic stimuli. Cardiovasc Res. 117:1339–1357. 2021. View Article : Google Scholar : PubMed/NCBI
17	Chen WX, Zhou J, Zhou SS, Zhang YD, Ji TY, Zhang XL, Wang SM, Du T and Ding DG: Microvesicles derived from human Wharton's jelly mesenchymal stem cells enhance autophagy and ameliorate acute lung injury via delivery of miR-100. Stem Cell Res Ther. 11:1132020. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Hu L, Huang H, Yu Y, Wang J, Yu Y, Li K, Li Y, Tian T and Chen F: CAR (CARSKNKDC) peptide modified ReNcell-derived extracellular vesicles as a novel therapeutic agent for targeted pulmonary hypertension therapy. Hypertension. 76:1147–1160. 2020. View Article : Google Scholar : PubMed/NCBI
19	Rashed WM, Hamza MM, Matboli M and Salem SI: MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: A systematic review. Cancer Metastasis Rev. 38:771–782. 2019. View Article : Google Scholar : PubMed/NCBI
20	Luo P, Jiang C, Ji P, Wang M and Xu J: Exosomes of stem cells from human exfoliated deciduous teeth as an anti-inflammatory agent in temporomandibular joint chondrocytes via miR-100-5p/mTOR. Stem Cell Res Ther. 10:2162019. View Article : Google Scholar : PubMed/NCBI
21	Alrfaei BM, Clark P, Vemuganti R and Kuo JS: MicroRNA miR-100 decreases glioblastoma growth by targeting SMARCA5 and ErbB3 in tumor-initiating cells. Technol Cancer Res Treat. 19:15330338209607482020. View Article : Google Scholar : PubMed/NCBI
22	Huang C, Qin X, Zhao N, Jin H, Zhang S and Yang H: MicroRNA-100 functions as a tumor suppressor in cervical cancer via downregulating the SATB1 expression and regulating AKT/mTOR signaling pathway and epithelial-to-mesenchymal transition. Oncol Lett. 20:1336–1344. 2020. View Article : Google Scholar : PubMed/NCBI
23	Gebeshuber CA and Martinez J: miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene. 32:3306–3310. 2013. View Article : Google Scholar : PubMed/NCBI
24	Jiang Q, He M, Guan S, Ma M, Wu H, Yu Z, Jiang L, Wang Y, Zong X, Jin F and Wei M: MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway. Tumour Biol. 37:5001–5011. 2016. View Article : Google Scholar : PubMed/NCBI
25	Steber HS, Gallante C, O'Brien S, Chiu PL and Mangone M: The C. elegans 3′UTRome v2 resource for studying mRNA cleavage and polyadenylation, 3′-UTR biology, and miRNA targeting. Genome Res. 29:2104–2116. 2019. View Article : Google Scholar : PubMed/NCBI
26	Horimoto Y, Sasahara N, Sasaki R, Hlaing MT, Sakaguchi A, Saeki H, Arakawa A, Himuro T and Saito M: High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. Breast Cancer Res Treat. 183:41–48. 2020. View Article : Google Scholar : PubMed/NCBI
27	Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, et al: FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci USA. 116:26823–26834. 2019. View Article : Google Scholar : PubMed/NCBI
28	Jing X, Liang H, Hao C, Hongxia L and Cui X: Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer. Aging (Albany NY). 11:7442–7456. 2019. View Article : Google Scholar : PubMed/NCBI
29	Petrelli A, Bellomo S, Sarotto I, Kubatzki F, Sgandurra P, Maggiorotto F, Di Virgilio MR, Ponzone R, Geuna E, Galizia D, et al: MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. ESMO Open. 5:e0009372020. View Article : Google Scholar : PubMed/NCBI